|In vitro (25°C)||DMSO||72 mg/mL (199.18 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||72 mg/mL (199.18 mM)|
|In vivo||30% propylene glycol, 5% Tween 80, 65% D5W||15 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||27.66 mL||138.31 mL||276.63 mL|
|0.5 mM||5.53 mL||27.66 mL||55.33 mL|
|1 mM||2.77 mL||13.83 mL||27.66 mL|
|5 mM||0.55 mL||2.77 mL||5.53 mL|
*The above data is based on the productmolecular weight 361.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineopla…
R547 is a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs) (Ki = 1, 3, and 1 nM for CDK1, CDK2, …
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
SNS-032 (BMS-387032) is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibit…
BAY 1000394 is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protei…